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Phase II trial of gemcitabine and irinotecan in previously treated 
patients with small-cell lung cancer
Okano, Yoshio; Horiike, Atsushi; Ohyanagi, Fumiyoshi; Satoh, 
Yukitoshi; Okumura, Sakae; Ishikawa, Yuichi; Nakagawa, Ken; Horai, 
Takeshi; Nishio, Makoto 
Cancer Institute Hospital, Tokyo, Japan
Background: Gemcitabine and irinotecan has been shown to have an 
antitumor activity as a single agent against previously treated SCLC. 
The objective of this study was to assess the efﬁcacy and safety of 
gemcitabine combined with irinotecan in patients with refractory or 
relapsed SCLC. 
Methods: Patients with histologically or cytologically conﬁrmed 
SCLC, 20 to 74 years in age, performance status 0-2, with a history of 
receiving one platinum-based chemotherapy were eligible for the study. 
Treatment consisted of gemcitabine (1,000 mg/m2) and irinotecan (150 
mg/m2) on days 1 and 15 of a 28-day cycle.The primary endpoint was 
the response rate (RR), and planned sample size for this phase II study 
was 30 patients (Simon’s two-stage minimax design).
Results: Thirty-one patients were enrolled and 30 patients (24 males/6 
females, 10 refractory/20sensitive, median age, 65 years) receive pro-
tocol treatment in this phase II trial. The median treatment cycles were 
3 (1-10). The overall response rates was obtained in 39.3% (95% CI: 
18.1% to 60.5%) of the patients, including two patients with refractory 
disease and 9 patients with sensitive disease. The median overall sur-
vival time was 14.4 months, and the 1-year survival rate was 51%. The 
median survival time of the patients with refractory disease was 7.4 
months, compared with 14.4 months for patients with sensitive disease. 
The chief grade 3/4 toxicities included neutropenia (42%), thrombo-
cytopenia (3%), diarrhea (9%), and liver dysfunction (3%). The only 
grade 4 toxicities were one case of grade 4 neutropenia (3.3%) and one 
case of grade 4 thrombocytopenia (3.3%).
Conclusion: Gemcitabine plus irinotecan is an active regimen that 
seems to be well-tolerated by patients with previously treated SCLC.
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Irinotecan plus carboplatin for patients with extensive-disease 
small cell lung cancer
Kim, Young Saeng; Lee, Yuna; Han, Sang Hoon; Park, Se Hoon; Park, 
Jinny; Cho, Eun Kyung; Shin, Dong Bok; Lee, Jae Hoon 
Division of Hematology and Oncology, Internal Medicine, Gachon 
University Gil Medical Center, Incheon, Korea
Background: To evaluate the activity and tolerance of irinotecan in 
combination with carboplatin in previously-untreated, extensive-dis-
ease small cell lung cancer (ED-SCLC).
Methods: Forty-four consenting patients with histologically conﬁrmed 
ED-SCLC received irinotecan 60 mg/m2 on days 1, 8 and 15 every 4 
weeks, plus carboplatin AUC 5.5 on day 1. Therapy was repeated until 
disease progression, unacceptable toxicity, or for up to 6 cycles.
Results: The patients’ median age was 66 years (range, 42-75) and the 
ECOG performance status was 0 for 1, 1 for 27 and 2 for 16. Nineteen 
patients (43%) had weight loss ≥5% at baseline. Twenty-nine objective 
responses (66%; 95% conﬁdence interval [CI], 52-80%), including 8 
complete responses, were achieved. With a median follow-up duration 
of 15 months, the median progression-free and overall survival was 6 
months (95% CI, 5-7) and 9 months (95% CI, 8-10), respectively. In to-
tal, 161 chemotherapy cycles were given (median, 4; range, 1-6). Toxic 
effects were mainly gastrointestinal, including anorexia and diarrhea. 
Two possible treatment-related deaths were observed (pneumonia and 
cerebral hemorrhage).
Conclusion: The combination chemotherapy with irinotecan and car-
boplatin is active and well-tolerated in patients with ED-SCLC.
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Phase II study of sequential topoisomerase targeting regimens with 
irinotecan/oxaliplatin followed by etoposide/carboplatin in patients 
with extensive small cell lung cancer (SCLC) 
Robert, Francisco; Harper, Karen; Wang, Deli 
University of Alabama at Birmingham Comprehensive Cancer Center, 
Birmingham, AL, USA
Background: Topoisomerase (Top) inhibitors are active agents in 
SCLC, and preclinical models indicate that the sequential adminis-
tration of Top I- and Top II- targeting drugs can result in additive or 
synergistic antitumor activity. The primary objective of this study was 
to determine the objective response rate of sequential irinotican/oxali-
platin (I/O-Regimen A) followed by etoposide/carboplatin (E/C-Regi-
men B) in patients with extensive SCLC. 
Methods: A treatment-cycle consisted of Regimen A®B: I-150-200 
mg/m2 (d1), O- 85 mg/m2 (d1), E- 100 mg/m2/d (d15, 16, 17), and C-
AUC of 6 (d15). Pegﬁlgrastin 6 mg was administered on d2, 18 of each 
cycle. Subsequent cycle of therapy was initiated 21 days after Regimen 
B; and assessment of response was performed after every 2 cycles. 
Refractory or relapsed patients were treated with Regimen A only. 
Results: Demographic characteristics of 16 patients enrolled are: me-
dian age, 58 years; gender ratio (male/female), 8/8; performance status 
0-1, 15 patients; and prior chemotherapy, 3 patients. Fifteen patients are 
currently evaluable for toxicity, and 12 patients for response. Toxicity 
(grade 3/4) during the 1st cycle of therapy includes: Regimen A-ANC 
(N=2), Fatigue (N=1); Regimen B-Hgb (N=1), ANC (N=3), Plt (N=4), 
and Fatigue (N=1).
The most signiﬁcant overall toxicity with Regimen A includes mild 
to moderate nausea-vomiting and anemia; grade 4 thrombocytopenia 
was the main dose-limiting toxicity with Regimen B. Response data 
in evaluable chemotherapy-naïve patients that have received ≥2 cycles 
of treatment includes (N=9): 5 partial responses, 3 stable disease, and 
1 progressive disease. No objective responses were observed in those 
patients with prior chemotherapy (N=3). 
Conclusions: Thrombocytopenia during Regimen B was the main 
limiting factor for dose intensiﬁcation. Early response data indicates 
that this sequential approach is active in chemotherapy naive patients 
with SCLC. This study is actively enrolling patients, and updated ef-
ﬁcacy/toxicity information, including time to progression and survival, 
will be presented.
